DEME is transforming from a dredging stalwart into a high-spec offshore wind “picks-and-shovels” leader—yet trades at a conglomerate discount driven by overstated US political risk.
Overview
DEME Group has undergone a decisive transformation from a traditional dredging contractor into a critical engineering and logistics platform for the “industrialization of the oceans,” with offshore wind now driving margin expansion and potential multiple re-rating. The investment case is framed as a barbell: Dredging & Infra offers a steady, inflation-hedged, cash-generative foundation supported by secular needs in coastal defense (sea-level rise) and port/trade infrastructure; Offshore Energy provides high-growth upside as global offshore wind deployment faces a structural shortage of high-spec installation and cable-laying vessels. Operational and financial results show a step-change: FY2024 turnover rose 25% to exceed €4B, H1 2025 revenue grew another 10% to €2.1B, and group EBITDA margin expanded to a record 21.9% (breaking the historical 17–18% band), reflecting improved utilization, execution, and mix. Offshore Energy in particular delivered explosive H1 2025 performance (revenue +27% YoY; EBITDA margin 31.4% vs 18.3%), supported by high fleet utilization, differentiated assets (Orion, Green Jade), and strong contractual protections (including a US cancellation fee). Strategically, the Havfram acquisition (~€900M including vessel CAPEX) is positioned as a consolidation masterstroke, adding two next-gen WTIVs (deliveries late 2025/early 2026) and reinforcing pricing power amid an industry “arms race” toward 15MW+ turbines. Despite strong fundamentals and a robust €7.5B order book, investor sentiment has been pressured by US policy uncertainty after 2025 offshore wind lease pauses/stop-work orders under the Trump administration. The report argues the market is over-indexing on US political risk (Americas ~10% of order book) and underappreciating tight European/Asian supply chains and DEME’s dominant high-spec position, creating a valuation disconnect and asymmetric opportunity for patient capital.